Baldrige Asset Management’s United Therapeutics UTHR Stock Holding History

Baldrige Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$0	Buy	+2	New	+$493	﹤0.01%	463

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Baldrige Asset Management's UTHR Position: Q1 2023 in Review

Baldrige Asset Management opened a new position in United Therapeutics (UTHR) in Q1 2023: 2 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #463 among its holdings.

506 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

Baldrige Asset Management held 2 shares of United Therapeutics worth $0 as of Q1 2023.
United Therapeutics was a new Baldrige Asset Management position in Q1 2023.
United Therapeutics made up ﹤0.01% of Baldrige Asset Management's portfolio in Q1 2023, its #463 holding.
506 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Baldrige Asset Management's 13F filing for Q1 2023, filed 17 Apr 2023.